SNP
|
Gene
|
Genotypes
|
Genotypes (na)
|
Genotypes (nb)
|
IgG (RI)
|
IgG1 (RI)
|
IgG2 (RI)
|
IgG3 (RI)
|
IgG4 (RI)
|
IgM (RI)
|
---|
rs35593994
|
CD28
|
GG/GA/AA
|
86/80/12
|
42/39/8
|
1.02/1.03/1.11
|
1.11/1.10/0.89
|
0.92/0.93/0.80
|
0.76/0.86/0.64
|
0.77/0.83/0.74
|
0.66/0.86/1.13c
|
rs3116496
|
CD28
|
TT/TC/CC
|
118/54/6
|
60/27/2
|
1.04/1.02/0.91
|
1.06/0.98/3.13d
|
0.91/0.92/0.95
|
0.82/0.72/0.75
|
0.82/0.75/0.67
|
0.83/0.70/0.65
|
rs733618
|
CTLA4
|
TT/TC/CC
|
135/20/2
|
72/7/1
|
1.06/0.89/1.05
|
1.11/0.97/0.81
|
0.87/1.18/0.64e
|
0.80/0.66/0.57
|
0.80/0.68/0.62
|
0.82/0.72/1.25
|
rs11571316
|
CTLA4
|
GG/GA/AA
|
59/75/12
|
29/39/4
|
1.04/1.03/0.97
|
1.17/1.10/0.84
|
0.96/0.95/0.68
|
0.74/0.86/0.56
|
0.73/0.82/0.66
|
0.81/0.75/0.79
|
rs5742909
|
CTLA4
|
CC/CT/TT
|
151/27/0
|
75/14/0
|
1.15/1.01/–
|
1.04/1.29/–
|
0.91/0.93/–
|
0.80/0.76/–
|
0.80/0.78/–
|
0.79/0.78/–
|
rs231775
|
CTLA4
|
AA/AG/GG
|
75/84/19
|
40/41/8
|
1.07/1.00/1.01
|
0.96/1.22/0.98
|
0.87/0.98/0.82
|
0.78/0.82/0.70
|
0.79/0.79/0.81
|
0.79/0.75/0.89
|
rs4675378
|
ICOS
|
TT/TC/CC
|
77/73/27
|
35/38/16
|
1.00/1.05/1.09
|
1.08/1.12/0.99
|
0.86/0.94/0.96
|
0.73/0.90/0.67
|
0.80/0.78/0.80
|
0.80/0.73/0.85
|
rs1129055
|
CD86
|
GG/GA/AA
|
110/60/8
|
53/31/5
|
1.00/1.08/1.15
|
1.08/1.09/1.06
|
0.93/0.90/0.93
|
0.78/0.82/0.70
|
0.82/0.76/0.70
|
0.81/0.73/0.90
|
rs1883832
|
CD40
|
CC/CT/TT
|
135/37/6
|
65/20/4
|
1.01/1.06/1.25
|
1.11/1.03/0.86
|
0.92/0.95/0.68
|
0.81/0.77/0.65
|
0.81/0.75/0.79
|
0.80/0.69/1.13
|
rs9514828
|
BLYS
|
CC/CT/TT
|
103/62/13
|
48/35/6
|
0.99/1.07/1.15
|
0.99/1.23/0.98
|
0.91/0.94/0.83
|
0.82/0.69/1.11
|
0.76/0.81/0.92
|
0.73/0.83/0.95
|
-
aNumber of individuals evaluated for ICB2-5-specific IgM and total IgG (n = 178)
-
bNumber of individuals evaluated for ICB2-5-specific IgG subclasses (n = 90)
-
cSignificant according to the dominant model (p = 0.033)
-
dSignificant according to the recessive model (p = 0.00004)
-
eSignificant according to the overdominant model (p = 0.042)